Can this proposal be signed electronically?

Yes. Electronic signatures are legally valid in the United States under the ESIGN Act (15 U.S.C. ch. 96) and UETA where adopted. Ensure intent, consent, attribution, and retention are captured to meet legal-validity tests.

Are additional disclosures required for consumers or patients?

For consumer-facing records or patient consent that shift to electronic-only delivery, comply with ESIGN consumer disclosure requirements and obtain the recipient's consent to electronic records per 15 U.S.C. §7001(c).

How should protected health information be handled?

Follow HIPAA privacy and security requirements; signed packages containing PHI require appropriate administrative, physical, and technical safeguards and a signed BAA when using third-party services (45 CFR §164.502 et seq.).

What authentication strength is advisable?

Use at least email-plus-SMS one-time passcode for routine submissions; higher-risk records may require multi-factor or certificate-based authentication to strengthen attribution.

Can signed records be amended after submission?

Yes, but amendments should be documented as controlled revisions with new versioning, dates, and signatures; retain the original signed record and the amendment trail for inspection.

How long must I keep signed proposals?

Retain per applicable federal and industry rules: IRS records three years (IRC §6501(a)), HIPAA records six years (45 CFR §164.530(j)), and longer when required by contract or state law.

Electronic Signature
Templates
Healthcare
Healthcare FDA Proposal

Healthcare FDA Proposal

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

HEALTHCARE FDA PROPOSAL

Applicant Information

Organization Name Primary Contact Name Contact Title Address

Phone

Email

Proposal Summary

Brief summary of proposal and regulatory purpose:

Product / Intervention Details

Product Name Product Type (select all that apply)

Device
Drug
Biologic
Combination Product
Diagnostic
Other (specify below)

Proposed Indication for Use Proposed Regulatory Pathway (select all that apply)

510(k)
De Novo
PMA
IND
NDA
EUA
Other:

Target Population & Representative Patient Information

Provide a representative example of a typical patient for proposed studies. This is illustrative only and will be redacted from public record if confidentiality is claimed below.

Patient Full Name

Date of Birth

Gender

Patient Address

Phone

Emergency Contact

Insurance & Coverage (Representative Patient)

Insurance Provider

Policy Number

Group Number

Subscriber Name

Medical History (Representative Patient)

Current Medications Allergies Prior Surgeries / Procedures Chronic Conditions

Preclinical & Clinical Data

Summary of Preclinical Studies Summary of Clinical Data Known Adverse Events / Safety Profile

Manufacturing, Controls & Labeling

Manufacturing Facilities and Controls Proposed Labeling / Instructions for Use

Clinical Study Design

Study Type (select all that apply)

Randomized Controlled Trial
Single-arm Study
Observational Study
PK/PD Study
Other:

Planned Number of Subjects

Study Duration (months)

Key Inclusion / Exclusion Criteria (summary) Primary and Secondary Endpoints Monitoring and Safety Plan

Risk/Benefit Assessment

Proposed Questions / Requested Actions

State specific regulatory questions for discussion and the actions being requested from the agency (meeting type, review pathway confirmation, data acceptability, etc.).

Attachments Checklist

Device/Product Description
Manufacturing Information and Quality Controls
Preclinical Study Reports
Clinical Study Reports / Data Listings
Proposed Labeling / Instructions for Use
Draft Informed Consent / Patient Materials
Other (describe below)

Confidentiality Claim & Certifications

The applicant hereby certifies that, to the best of its knowledge, the information and data provided in this proposal are true, complete, and accurate. Applicant represents that it has authority to submit this proposal on behalf of the organization identified above. The applicant acknowledges that this submission is a pre-submission communication and does not constitute a formal marketing application; regulatory fees, formal submissions, and required forms remain the applicant's obligation. Where confidentiality is claimed for specific documents or data submitted in connection with this proposal, the applicant has clearly identified those materials and provided a concise justification for confidential treatment. The applicant understands that certain information may be subject to public disclosure under applicable law and that the agency may request redaction justifications.

Authorization Expiration Date (if applicable)

Applicant agrees to promptly notify the agency of any materially adverse new information arising after submission and to provide complete, updated data upon request. Applicant further certifies that any human subject data submitted were obtained in compliance with applicable human subject protections and that the described studies were conducted under appropriate ethical oversight.

Applicant Representative:

By:

Date:

What a Healthcare FDA Proposal Is and When It’s Used

A Healthcare FDA Proposal is a formal, structured submission prepared by sponsors, manufacturers, or clinical teams to present a medical product development plan, clinical study design, regulatory strategy, or labeling change to the U.S. Food and Drug Administration. It consolidates scientific rationale, proposed methods, safety monitoring, statistical approach, and supporting data to request feedback, a pre-submission meeting, investigational device exemption (IDE) consideration, or to inform market-authority pathways. The document frames questions for reviewers, documents commitments and timelines, and identifies required attachments for agency review.

Why a Clear Proposal Matters for FDA Review

A well-organized Healthcare FDA Proposal clarifies the regulatory pathway, concentrates evidence reviewers need, and reduces iterative information requests. Clear presentation of endpoints, risk controls, and data collection supports more efficient agency feedback and helps document sponsor commitments for testing, monitoring, and post-market obligations.

Core Sections Every Professional Healthcare FDA Proposal Should Include

Include sections that address science, safety, study design, regulatory strategy, data handling, and supporting attachments to meet FDA expectations and facilitate review.

Executive Summary

Concise description of product, objectives, requested FDA action, key endpoints, and the regulatory pathway sought; frames reviewer expectations and decision points.

Clinical Background

Summarize disease area, unmet need, prior clinical evidence, relevant literature, and rationale for the proposed intervention and chosen endpoints.

Study Design

Detail population, inclusion/exclusion criteria, sample size rationale, endpoints, statistical plan, monitoring, and planned analyses for reviewer evaluation.

Regulatory Strategy

Explain intended pathway (e.g., pre-sub, IDE, 510(k), PMA, NDA), applicable guidance, predicate devices or reference products, and planned regulatory milestones.

Safety Monitoring

Describe adverse event reporting, data safety monitoring board (DSMB) roles, interim analyses, stopping rules, and post-market commitments if applicable.

Supporting Attachments

List protocols, informed consent templates, investigator brochures, preclinical reports, device specs, labeling drafts, and any required forms or checklists.

Sequential Steps to Prepare and Submit the Proposal

Follow a clear sequence from internal review and attachments assembly to signatures, validation, and final electronic submission to minimize rework.

01

Define Scope: Confirm objectives, endpoints, and required regulatory pathway.
02

Assemble Evidence: Collect protocols, safety data, manufacturing details, and prior studies.
03

Internal Review: Legal, quality, and regulatory teams verify completeness and consistency.
04

Sign and Submit: Use compliant eSignature and transmit with audit trail for filing.

How Digital Preparation and eSubmission Typically Flow

An electronic workflow preserves audit trails and reduces manual handling; typical stages include document assembly, signer placement, authentication, and delivery to reviewers.

Assemble: Compile PDF/A files and supporting exhibits.
Place Fields: Insert signature, date, and initials fields where required.
Authenticate: Choose signer authentication level (email, SMS, or stronger).
Deliver: Send final package with audit trail attached.

Recommended Digital Workflow Settings for Regulatory Packages

Configure authentication, file formats, audit capture, retention, and integrations to meet FDA and internal compliance requirements.

Field	Configuration
Authentication	Email link plus SMS one-time passcode where available
File Format	PDF/A preferred for long-term preservation and reproducibility
Audit Trail	Full event log with timestamps, IP, and signer attribution
Integrations	EHR, Google Workspace, Salesforce, NetSuite, or document repositories

Platform and Integration Considerations for eSigning

Ensure the chosen configuration captures immutable audit trails, supports your retention policy, and can export signed records for archiving and inspection.

File Formats: PDF, PDF/A, DOCX supported
Integrations: Salesforce, NetSuite, Microsoft 365, Google Workspace
Security: AES-256 at rest, TLS 1.2/1.3 in transit

Comparing eSignature Vendor Pricing and Core Features

Basic pricing and feature availability for common eSignature vendors; signNow is listed first per comparison conventions.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	Varies	Varies	Varies	Varies
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No
Envelope Cap	No cap	100 envelopes/user/year	Varies	Varies	Varies

Security Controls and Certifications Relevant to Healthcare Proposals

Encryption: TLS 1.2/1.3 in transit; AES-256 at rest

HIPAA: HIPAA compliant; BAA available when required

21 CFR Part 11: Supports controls for FDA-regulated electronic records

SOC 2: SOC 2 Type II report available on request

ISO: ISO 27001 certified

Accessibility: WCAG 2.0 Level AA compliance

Key Risks from Incomplete or Incorrect Proposals

Submission Rejection: Missing mandatory attachments

Review Delays: Inconsistent data across files

Regulatory Findings: Failure to address safety monitoring

Data Integrity: Unsigned or improperly signed records

HIPAA Exposure: Inadequate PHI controls

Legal Exposure: Misrepresentation or inconsistent claims

Common Preparation Mistakes to Avoid

Submitting draft protocols without finalized safety monitoring plans, which often triggers agency clarification requests and prolongs review time.
Using inconsistent sponsor or product names across attachments, which can prevent proper cross-referencing and create administrative rejection risks.
Failing to include clear data tables or statistical analysis plans, forcing reviewers to request additional detail and delaying substantive feedback.
Not capturing an auditable signature trail or using initials where signatures are required, complicating downstream inspection or audit responses.

Typical Roles Responsible for Drafting and Signing the Proposal

Coordinate these contributors early, assign clear ownership for each section, and confirm signing authority before finalizing the package.

Regulatory affairs professionals who align the submission with applicable FDA guidance and manage agency interactions.
Clinical operations and medical leads who define study design, safety monitoring, and protocol elements.
Legal and quality assurance teams who ensure completeness, contract terms, and compliance with privacy and recordkeeping rules.

Representative Signers and Their Responsibilities

Regulatory Affairs Director

Leads regulatory strategy, reviews proposal text for compliance with FDA guidance, coordinates pre-submission interactions, and generally signs or certifies regulatory sections for submission.

Clinical Trials Coordinator

Compiles protocol details, confirms study logistics and data collection plans, verifies investigator commitments, and provides technical attachments supporting clinical sections.

Real-World Examples of Electronic Proposal Workflows

These concise examples illustrate how organizations used electronic workflows to assemble, sign, and manage regulatory proposal packages.

Optica Ventures

Optica Ventures consolidated vendor and study contracts into a single electronic package to speed approvals and reduce routing complexity.

The process reduced turnaround on executed agreements by consolidating attachments and digital signatures.
Brian Fitzgibbons, COO, noted the interface is simple and easy-to-use for the internal team and customers, supporting faster execution without sacrificing documentation or auditability.

Fertility Centers of Illinois

A clinical services organization standardized consent and vendor proposals using an eSignature-enabled workflow to ensure consistent templates and audit trails.

Standard templates reduced errors in repeated submissions.
John Butler, Founder, reported responsive support and reliable API integrations that helped the organization maintain compliance while streamlining administrative processing.

Practical Tips for Accurate and Efficient Proposal Completion

Adopt consistent templates, centralize attachments, and validate signer authority to reduce review cycles and compliance risk.

Use Standard Templates

Maintain a controlled template for clinical protocols and informed consent; versioning reduces inconsistencies and supports faster internal review and sign-off.

Verify Signer Authority

Confirm each signer's legal authority and title in advance, and capture delegation of authority when signers act on behalf of others.

Consolidate Exhibits

Bundle laboratory, manufacturing, and preclinical reports as indexed exhibits to make review navigation easier and reduce missing-document responses.

Preserve Audit Trails

Ensure the platform records timestamps, IP addresses, and authentication events to support regulatory inspection and internal audit needs.

Typical Timelines and What to Expect During Review

Plan internal and external milestones so reviewers have adequate time to assess the scientific and regulatory elements of your submission.

Internal Review Window:

Allow 2–4 weeks for legal, quality, and clinical sign-off before external submission

FDA Pre-Submission:

Expect scheduling and response timelines to vary; allow multiple weeks for meeting preparation

510(k) Review Target:

FDA has an approximate 90-day target review period for 510(k) submissions

PMA/IDE Reviews:

Longer and more resource-intensive; timelines vary by complexity and user fees

Post-Submission Queries:

Allow ongoing time for sponsor responses to information requests during review

Key Milestones from Drafting to Final Record

Track milestones from draft completion through signature, submission, and final archiving to ensure traceability and compliance.

01

Draft Complete

Finalize text and attachments ready for internal circulation

02

Internal Approval

Legal, QA, and clinical approvals secured before signature

03

Signatures Obtained

Capture electronic signatures and confirm audit trail integrity

04

Record Archival

Export signed package and store according to retention policy

Common Questions and Practical Answers About FDA Proposal Workflows

Answers to frequent procedural and legal questions when preparing, signing, and retaining Healthcare FDA Proposals.

Need help? Contact support

Can this proposal be signed electronically?
Yes. Electronic signatures are legally valid in the United States under the ESIGN Act (15 U.S.C. ch. 96) and UETA where adopted. Ensure intent, consent, attribution, and retention are captured to meet legal-validity tests.
Are additional disclosures required for consumers or patients?
For consumer-facing records or patient consent that shift to electronic-only delivery, comply with ESIGN consumer disclosure requirements and obtain the recipient's consent to electronic records per 15 U.S.C. §7001(c).
How should protected health information be handled?
Follow HIPAA privacy and security requirements; signed packages containing PHI require appropriate administrative, physical, and technical safeguards and a signed BAA when using third-party services (45 CFR §164.502 et seq.).
What authentication strength is advisable?
Use at least email-plus-SMS one-time passcode for routine submissions; higher-risk records may require multi-factor or certificate-based authentication to strengthen attribution.
Can signed records be amended after submission?
Yes, but amendments should be documented as controlled revisions with new versioning, dates, and signatures; retain the original signed record and the amendment trail for inspection.
How long must I keep signed proposals?
Retain per applicable federal and industry rules: IRS records three years (IRC §6501(a)), HIPAA records six years (45 CFR §164.530(j)), and longer when required by contract or state law.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now